Pembrolizumab Bests Chemotherapy in PD-L1 Expressing NSCLC

John SchieszerJun 3, 2018Pembrolizumab represents a new standard first-line treatment option for PD-L1 –expressing advanced/metastatic NSCLC, according to KEYNOTE-042 investigators.

Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news